Targeting the eicosanoid pathway in hepatocellular carcinoma

Area of Science:

• Hepatology and Cancer Biology
• Molecular Biology and Biochemistry

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge with high mortality.
• Advanced HCC stages have limited therapeutic options, with current treatments offering marginal survival benefits and potential toxicity.
• Chronic liver injury from factors like viral hepatitis, alcohol, and non-alcoholic fatty liver disease (NAFLD) drives inflammation, fibrosis, cirrhosis, and HCC development.

Purpose of the Study:

• To review the eicosanoid pathway's role in liver disease progression and hepatocellular carcinoma (HCC) development.
• To elucidate the mechanisms by which eicosanoid pathway members influence liver diseases, focusing on NAFLD, fibrosis, cirrhosis, and HCC.
• To identify potential therapeutic targets within the eicosanoid pathway for advanced HCC.

Main Methods:

• Literature review of the eicosanoid pathway.
• Analysis of the link between the eicosanoid pathway, inflammation, and liver diseases (NAFLD, fibrosis, cirrhosis, HCC).
• Identification of key eicosanoid pathway components relevant to HCC pathogenesis.

Main Results:

• The eicosanoid pathway is intricately linked to inflammation and carcinogenesis in the liver.
• Specific members of the eicosanoid pathway can either promote or inhibit the development of liver diseases and HCC.
• Understanding these mechanisms highlights the pathway's potential in disease progression.

Conclusions:

• The eicosanoid pathway represents a promising area for novel therapeutic strategies in advanced HCC.
• Targeting specific components of this pathway could offer new treatment avenues for patients with limited options.
• Further research into the eicosanoid pathway's role in liver disease and cancer is warranted.